Elke Pfaff

Elke Pfaff

Auto-generated profile, based on publicly available information

Elke Pfaff

Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital , Heidelberg

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in JCO Precision Oncology
Verified
Journal Article
Closed access
AHAnna-Elisa Heipertz
Anna-Elisa Heipertz
Kristian W. PajtlerKristian W. Pajtler
Kristian W. Pajtler
EPElke Pfaff
Elke Pfaff
KSKathrin Schramm
Kathrin Schramm
MBMirjam Blattner-Johnson
Mirjam Blattner-Johnson
CTCornelis M. van Tilburg
Cornelis M. van Tilburg
PURPOSE: INFORM is an international pediatric precision oncology registry, prospectively collecting molecular and clinical data of children with recurrent, progressive, or very high-risk malignancies. We have previously identified a subgroup of patients with improved outcomes on the basis of molecular profiling. The present analysis systematically investigates progression-free survival (PFS) and overall survival (OS) of patients receiving matching targeted treatment (MTT) with the most frequently applied drug classes and its correlation with underlying molecular alterations. METHODS: A cohort of 519 patients with relapsed or refractory high-risk malignancies who had completed a follow-up of at least 2 years or shorter in the case of death or loss to follow-up was analyzed. Survival times were compared using the log-rank test. RESULTS: MTT with anaplastic lymphoma kinase (ALK), neurotrophic tyrosine receptor kinase (NTRK), and B-RAF kinase (BRAF) inhibitors showed significantly improved PFS ( P = .012) and OS ( P = .036) in comparison with conventional treatment or no treatment. However, analysis of the four most commonly applied MTT groups, mitogen-activated protein kinase (MEK- n = 19), cyclin-dependent kinase (CDK- n = 23), other kinase (n = 62), and mammalian-target of rapamycin (mTOR- n = 20) inhibitors, did not reveal differences in PFS or OS compared with conventional treatment or no treatment in patients with similar molecular pathway alterations. We did not observe differences in the type of pathway alterations (eg, copy number alterations, single-nucleotide variants, InDels, gene fusions) addressed by MTT. CONCLUSION: Patients with respective molecular alterations benefit from treatment with ALK, NTRK, and BRAF inhibitors as previously described. No survival benefit was observed with MTT for mutations in the MEK, CDK, other kinase, or mTOR signaling pathways. The noninterventional character of a registry has to be taken into account when interpreting these data and underlines the need for innovative interventional biomarker–driven clinical trials in pediatric oncology.

3 December 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
ALAudrey-Anne Lamoureux
Audrey-Anne Lamoureux
MFMichael J. Fisher
Michael J. Fisher
LLLauriane Lemelle
Lauriane Lemelle
EPElke Pfaff
Elke Pfaff
PAPouneh Amir-Yazdani
Pouneh Amir-Yazdani
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.

12 March 2025 in Neuro-Oncology
Verified
Journal Article
Open access
MMMarion Mateos
Marion Mateos
PAPamela Ajuyah
Pamela Ajuyah
NFNoemi Fuentes-Bolanos
Noemi Fuentes-Bolanos
SESam El-Kamand
Sam El-Kamand
PBPaulette Barahona
Paulette Barahona
DZDavid Ziegler
David Ziegler
Background: Factors that drive the development of diffuse midline gliomas (DMG) are unknown. Our study aimed to determine the prevalence of pathogenic/likely pathogenic (P/LP) germline variants in pediatric patients with DMG. Methods: We assembled an international cohort of 252 pediatric patients with DMG, including diffuse intrinsic pontine glioma (n = 153), with germline whole genome or whole exome sequencing. Results: We identified P/LP germline variants in cancer predisposition genes in 7.5% (19/252) of patients. Tumor profiles differed, with the absence of somatic drivers in the PI3K/mTOR pathway in patients with germline P/LP variants versus those without (P = .023). P/LP germline variants were recurrent in homologous recombination (n = 9; BRCA1, BRCA2, PALB2) and Fanconi anemia genes (n = 4). Somatic findings established that the germline variants definitively contributed to tumorigenesis in at least 1% of cases. One patient with recurrent DMG and pathogenic germline variants (BRCA2, FANCE) showed a near-complete radiological response to PARP and immune checkpoint inhibition. Conclusions: Our study determined the prevalence of pathogenic germline variants in pediatric DMG and suggests a role in tumorigenesis for a subset of patients.

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
EPElke Pfaff
Elke Pfaff
TBTiphaine Adam de Beaumais
Tiphaine Adam de Beaumais
AMAntonin Marchais
Antonin Marchais
CTCornelis M. van Tilburg
Cornelis M. van Tilburg
MBMirjam Blattner-Johnson
Mirjam Blattner-Johnson
GVGilles Vassal
Gilles Vassal

3 February 2025
Verified
Other
Open access
ALAudrey-Anne Lamoureux
Audrey-Anne Lamoureux
MFMichael J. Fisher
Michael J. Fisher
LLLauriane Lemelle
Lauriane Lemelle
EPElke Pfaff
Elke Pfaff
PAPouneh Amir-Yazdani
Pouneh Amir-Yazdani
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.

3 February 2025
Verified
Other
Open access
ALAudrey-Anne Lamoureux
Audrey-Anne Lamoureux
MFMichael J. Fisher
Michael J. Fisher
LLLauriane Lemelle
Lauriane Lemelle
EPElke Pfaff
Elke Pfaff
PAPouneh Amir-Yazdani
Pouneh Amir-Yazdani
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
Supplementary Table S1. NTRK fusion type and histology.